🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

20 recruiting trials

for Biliary Tract Neoplasms Immunotherapy

Dynamic Prediction Model for Patients with Unresectable Biliary Malignancies Receiving Systemic Chemotherapy Combined with Immunotherapy: a Multicenter, Observational Study NCT06849193n/a2 sites📍 Nanjing📍 Nanjing Zhongda Hospital · Tests: Systemic chemotherapy combined with immunotherapy Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma NCT07780838Phase 21 site📍 Columbus Ohio State University Comprehensive Cancer Center · Tests: Biospecimen Collection, Cisplatin, Computed Tomography, Durvalumab, Gemcitabine Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study NCT07405086Phase 41 site📍 Portland OHSU Knight Cancer Institute · Tests: Biospecimen Collection, Immune Checkpoint Inhibitor Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC) NCT06564623Phase 11 site📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)], Durvalumab, Tremelimumab Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer NCT07670273Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Trastuzumab Rezetecan, Adebrelimab, Lenvatinib Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) NCT05451043Phase 21 site📍 Edmonton AHS Cancer Control Alberta · Tests: Durvalumab, Gemcitabine, Nab paclitaxel, Tremelimumab, Propranolol A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer. NCT07679399Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Durvalumab plus GEMOX/GC chemotherapy sequentially followed by lenvatinib, Capecitabine A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors NCT05592626Phase 1, Phase 219 sites📍 Sacramento📍 Celebration📍 Miami Marengo Therapeutics, Inc. · Tests: STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma NCT07030140Phase 21 site📍 Jinan Jinbo Yue · Tests: Stereotactic Body Radiotherapy (SBRT), Tislelizumab, Gemcitabine, Cisplatin or Oxaliplatin Prospective Cohort of Immune Checkpoint Inhibitor-induced Hepatitis NCT06864481n/a1 site📍 Montpellier University Hospital, Montpellier · Tests: Blood samples A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) NCT05849480Phase 1, Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: oxaliplatin, capecitabine, Keytruda, CDX-1140 MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma NCT07036380Phase 211 sites📍 Besançon📍 Dijon📍 Grenoble Centre Hospitalier Universitaire de Besancon · Tests: MP0317 + Gemcitabine + Cisplatine + Durvalumab, CT-Scan, Gemcitabine + Cisplatin + Durvalumab Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer NCT06230471Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Pembrolizumab,Lenvatinib and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）, Pembrolizumab and Lenvatinib, Pembrolizum… Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer NCT07025174Phase 21 site📍 Hangzhou First Affiliated Hospital of Zhejiang University · Tests: PD-1/CTLA-4 Dual Functional Antibody, Gemcitabine, Cisplatin, Anlotinib, Oxaliplatin + 5-Fluorouracil/Leucovorin A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors NCT06270706Phase 122 sites📍 New Haven📍 Atlanta📍 Grand Rapids Pliant Therapeutics, Inc. · Tests: PLN-101095, PLN-101095, PLN-101095, PLN-101095, PLN-101095 Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers NCT06001658Phase 21 site📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: Gemcitabine, Cisplatin, Pembrolizumab Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC NCT05733598Phase 212 sites📍 Beverly Hills📍 La Jolla📍 Miami Replimune, Inc. · Tests: RP2, Bevacizumab, Atezolizumab, Durvalumab, RP2 Monotherapy QL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer NCT07733115Phase 21 site📍 Shanghai Shanghai Zhongshan Hospital · Tests: Iparomlimab and Tuvonralimab (QL1706), Gemcitabine and Cisplatin Chemotherapy Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer NCT07636798Phase 1, Phase 21 site📍 Chengdu West China Hospital · Tests: HAIC Combined Regimen Treatment Group Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer NCT07704177Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Trastuzumab Rezetecan, Adebrelimab, Lenvatinib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy